From established players to emerging companies, Canada’s pharmaceutical landscape is diverse and dynamic.
Canadian pharmaceutical companies are working to discover and develop key innovations amid an increasingly competitive global landscape. Emerging technologies such as artificial intelligence are also playing a role in this area.
Here Investing News Network lists the top Canadian pharma stocks on the TSX and TSXV based on year-to-date gains; CSE stocks were considered, but this time none made it to the list. All data was compiled as of April 10, 2026 using TradingView stock screenerAnd companies with a market cap of more than C$10 million at that time were considered.
Read on to learn what drives the share prices of the best-performing Canadian pharma stocks.
1. Medexus Pharmaceuticals (TSX:MDP)
Profit year-on-year: 74.34 percent
market cap: C$125 million
Share Price: C$3.94
Medexus Pharmaceuticals is a specialty pharmaceutical company that acquires, develops and commercializes specialty and rare disease medicines in North America. The company has expertise in hematology, oncology, rheumatology, autoimmune diseases, allergy and dermatology. It focuses on bringing late-stage or already marketed products through licensing/partnerships and then handling regulatory approval and commercialization in Canada and the US.
GRAFAPEX, one of the most significant branded products in the Company’s portfolio, is a conditioning regimen used with fludarabine prior to allogeneic hematopoietic stem cell transplantation in patients with AML/MDS.
In Medexus results for Third fiscal quarter of 2026Management points to the continued strength of GRAFAPEX as a key driver of the company’s year-to-date performance.
2. Bioscientific (TSXV:RX)
year-on-year profit: : 46.63 percent
market cap: : C$173.84 million
share price: : C$15.25
Biocient is a specialty pharmaceutical company focused on licensing or acquiring established, high-margin health care products for the Canadian and international markets. Its growth is driven by iron health and women’s wellness brands. Its flagship brand, Feramax, has been Canada’s leading iron supplement for over a decade.
The company’s acquisition of Tibelia for the treatment of menopause symptoms in 2024 has been a key growth driver, 302 percent year-on-year Growth in international pharma sales in 2025.
In March, the company 44,222 restricted share units granted Strengthening long-term, performance-aligned compensation to directors, officers, management and employees under its three-year restricted share unit plan.
3. Knight Therapeutics (TSX:GUD)
year-on-year profit: : 29.95 percent
market cap: : C$749.97 million
share price: : C$7.55
Knight Therapeutics is a specialty pharmaceutical company headquartered in Montreal, Quebec.
It operates on an acquisition and in-licensing model, acquiring rights to innovative medicines from global pharmaceutical companies and commercializing them in Canada and Latin America.
The company was originally founded by former leaders of Paladin Labs, which was acquired by Endo International in 2014. In June 2025, Knight bought back paladin business Endo for C$107 million in cash, adding more than 40 products to its Canadian roster. These additions helped in driving Year-on-year revenue growth 21 percent In 2025, Knight reported C$450.09 million for the period.
Also driving that growth was one deal in mid-2025 With Sumitomo Pharma America.
4. Satellos Bioscience (TSXV:MSCL)
year-on-year profit: : 14.27 percent
market cap: : C$179.36 million
share price: : C$9.05
Satelos Bioscience is a Canadian pharmaceutical company that is expanding treatment options for muscle disorders.
The company focuses specifically on Duchenne muscular dystrophy, developing therapies that target specific biological pathways involved in regenerating and repairing muscle tissue. Its lead candidate, SAT-3247, targets a protein called AAK1, which regulates the activity of stem cells that activate and differentiate new muscle fibers.
In the fourth quarter of 2025, Satellos first dose given One patient in its 11-month open-label follow-up study for adults who has completed its initial Phase 1b trial. The purpose of the study is to demonstrate the lasting impact of the significant functional improvements observed at the beginning of the year.
In December 2025, the company New investigational drug approved from the US Food and Drug Administration and several other global regulators to initiate BASECAMP, a global Phase 2 randomized, placebo-controlled study to evaluate SAT-3247 in pediatric patients.
On February 12, Satellos reported that The first participant was dosed.
In its Latest Quarterly ReportReleased March 27, management said it expects cash, plus a Equity raise of US$57.2 million in FebruaryWill finance operations until 2027.
5. HLS Therapeutics (TSX:HLS)
Profit year-on-year: 10.71 percent
market cap: C$137.60 million
Share Price: C$4.55
HLS Therapeutics focuses on drugs for cardiovascular and central nervous system problems, often through partnerships. It specializes in acquiring and commercializing pharmaceuticals that address unmet needs, including Vascepa to reduce cardiovascular risk and Clozaril for treatment-resistant schizophrenia. Additionally, the Company generates revenue from a diverse portfolio of royalty interests on various products marketed by third parties.
Health Canada’s approval of LDL-cholesterol-lowering treatment Nilamdo in November 2025 represents the most significant catalyst for the company since the launch of Vascepa; HLS believes this milestone establishes it as a major leader in the Canadian cardiovascular market. Nilamdo had Commercial launch on March 5.
The company informed Essentially flat 2025 revenues at US$55.5 million, but adjusted EBITDA grew 18 percent to US$19.6 million and operating cash flow more than doubled
Don’t forget to follow us @INN_LifeScience For real time news updates!
Securities Disclosure: I, Megan Seiter, do not have any direct investment interest in any of the companies mentioned in this article.
From articles on your site
Related articles on the web
